Private Equity

A major partnership in Michigan and Ohio's ENT sector signals a growing trend: private equity-backed groups are reshaping independent medical practices.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

Developer Charles S. Cohen pays a massive personal debt to Fortress, ending a bitter legal war and narrowly avoiding receivership. A look at the brinksmanship in CRE finance.

A private equity-backed firm is buying local IT providers, signaling a structural shift in how our economy's digital backbone is built and managed.

With a new Deputy CEO and a shift for its COO, Exor is fortifying its core while positioning its fast-growing investment arm, Lingotto, for the future.

A top wealth firm's western expansion reveals a deeper trend: the future of managing fortunes lies in combining national resources with deep local roots.

A new survey reveals a startling trend: affluent Americans are planning their escape. We dig into the data, from war fears to tax woes, and the "Golden Visas" they're using.

InsuranceAUM.com's annual meeting reveals a powerful shift: prioritizing peer collaboration to navigate market turbulence and build a more resilient future.

As banking giants merge, United Development Bank secures FDIC approval to launch a new community-focused institution in Bellevue, betting on relationship banking and financial inclusion.

Private equity firm Oakline acquires a major affordable housing manager. Is this the future of community management or a simple play for scale?

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

As layoffs continue, a new guide reveals the critical mistake leaders make: ignoring the employees who stay. Here's how to rebuild trust and retain talent.

As institutional capital seeks refuge from market volatility, Stable Asset Management's $100M backing of Zenzic Capital signals a major bet on specialist credit.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

A landmark deal for Eos's zinc battery tech, backed by Cerberus capital, aims to solve Texas's grid woes and prove a new model for energy storage finance.

A public company is offering a volatile mix of OpenAI, Worldcoin, and MrBeast. We deconstruct the high-risk, high-reward strategy behind its unique treasury.

The appointment of Bethany Sensenig, a veteran of PE-backed turnarounds, signals CenExel is preparing for a major push to dominate the clinical research market.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

Verdantas' latest acquisition of New Jersey-based Yu & Associates signals a major push to dominate the Northeast's engineering and environmental market.

A PR firm launches a daily financial newsletter for the lower middle market, betting that speed and focus can win over dealmakers in a crowded, vital field.